Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaceutical works polpharma sa - bisoprolol a kyselina acetylsalicylová - 58 - hypotensiva

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaceutical works polpharma sa - bisoprolol a kyselina acetylsalicylová - 58 - hypotensiva

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - kyselina acetylsalicylová - 16 - anticoagulantia (fibrinolytica, antifibrinol.)

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

xantis pharma limited, cyprus - paracetamol, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Avrupa Birliği - Slovakça - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antitrombotické činidlá - kengrexal, súbežne s kyselinou acetylsalicylovou (asa) je indikovaný na redukciu trombotických kardiovaskulárnych príhod u dospelých pacientov s ischemickou chorobou srdca ktorí podstúpili perkutánna koronárna intervencia (pci), ktorí dostali ústneho p2y12 inhibítor pred pci procedúrou a u ktorých perorálna terapia s inhibítormi p2y12 nie je možné alebo žiaduce.

Slovakya - Slovakça - ŠÚKL (Štátny ústav pre kontrolu liečiv)

herbacos recordati s.r.o., Česká republika - kyselina acetylsalicylová, kombinácie s výnimkou psycholeptík - 07 - analgetica, antipyretica

Avrupa Birliği - Slovakça - EMA (European Medicines Agency)

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotické činidlá - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Avrupa Birliği - Slovakça - EMA (European Medicines Agency)

viatris limited - klopidogrel besilát - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidlá - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segment elevation akútnom infarkte myokardu v kombinácii s asa u medicínsky liečiť pacientov nárok na thrombolytic therapy. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. Ďalšie informácie nájdete v časti 5.